Active Ingredient(s): Ezogabine
FDA Approved: * June 10, 2011
Pharm Company: * VALEANT PHARMA
Category: Anticonvulsant

Retigabine (INN) or ezogabine (USAN) is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients.[2] The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline. It was approved by the European Medicines Agency under the trade name Trobalt on March 28, 2011, and by the United States Food and Drug Administration (FDA), under the trade name Potiga, on June 10, 2011. Production has been discontinued in June 2017.&a... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Potiga RTG;50
Potiga 50 mg Oral Tablet
NDC: 0173-0810
Glaxosmithkline LLC
Potiga RTG;200
Potiga 200 mg Oral Tablet
NDC: 0173-0812
Glaxosmithkline LLC
Potiga RTG;300
Potiga 300 mg Oral Tablet
NDC: 0173-0813
Glaxosmithkline LLC
Potiga 400 mg Oral Tablet
NDC: 0173-0814
Glaxosmithkline LLC